Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts)

被引：0
|
作者：
Delaloge, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Tedesco, K. L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Blum, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Goncalves, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Lubinski, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Efrat, N. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Osborne, C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Lebedinsky, C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Tercero, J. C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Holmes, F. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] US Oncol, New York Oncol Hematol, Albany, NY USA
[3] Baylor Sammons Canc Ctr, Texas Oncol, US Oncol, Dallas, TX USA
[4] Inst J Paoli I Calmettes, F-13009 Marseille, France
[5] Int Hereditary Canc Ctr, Szczecin, Poland
[6] Kaplan Med Ctr, Rehovot, Israel
[7] PharmaMar Colmenar Viejo, Madrid, Spain
[8] US Oncol Res, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1010
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase IV study evaluating effectiveness and safety of talazoparib in patients with locally advanced or metastatic HER2 negative breast cancer and a BRCA1 or BRCA2 mutation (ViTAL)
    Loirat, Delphine
    de labarre, Marie Duboys
    Essner, Christine
    Hrab, Ioana
    Thery, Jean-Christophe
    Jouannaud, Christelle
    Vuagnat, Perrine
    Soibinet-Oudot, Pauline
    Creisson, Anne
    Mailliez, Audrey
    Mouysset, Jean-Loup
    Salabert, Laura
    Dohollou, Nadine
    Fumet, Jean-David
    Rouge, Thibault De La Motte
    Vauthier, Jean-Michel
    Decrop, Maylis
    Pujol, Pascal
    CANCER RESEARCH, 2022, 82 (04)
  • [32] Multimodal iron oxide (Fe3O4)-saturated lactoferrin nanocapsules as nanotheranostics for real-time imaging and breast cancer therapy of claudin-low, triple-negative (ER-/PR-/HER2-)
    Kanwar, Jagat R.
    Kamalapuram, Sishir K.
    Krishnakumar, Subramanian
    Kanwar, Rupinder K.
    NANOMEDICINE, 2016, 11 (03) : 249 - 268
  • [33] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
    Rugo, Hope
    Bardia, Aditya
    Cortes, Javier
    Curigliano, Giuseppe
    Hamilton, Erika
    Hurvitz, Sara
    Loibl, Sibylle
    Tolaney, Sara
    Kaklamani, Virginia
    Tonini, Giulia
    Matheny, Shannon
    Theall, Kathy Puvana
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [34] A Phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER-2-positive metastatic breast cancer (MBC)
    Xu, L.
    Song, S.
    Zhu, J.
    Lu, R.
    Li, L.
    Jiao, S.
    Pan, H.
    Tao, M.
    Su, Y.
    Liu, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 125 - 125
  • [35] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Xu, L
    Song, S
    Zhu, J
    Luo, R
    Li, L
    Jiao, S
    Pan, H
    Tao, M
    Su, Y
    Liu, D
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S94
  • [36] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (PTS) with HER2-positive metastatic breast cancer (MBC)
    Xu, Ligong
    Song, Santai
    Zhu, Jianxin
    Luo, Rongcheng
    Li, Lejing
    Jiao, Sunchang
    Chen, Li
    Tao, Min
    Su, Yongqian
    Liu, Duanqi
    ANNALS OF ONCOLOGY, 2006, 17 : 76 - 77
  • [37] Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study
    Rugo, Hope S.
    O'Shaughnessy, Joyce
    Cortes, Javier
    Bardia, Aditya
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Kaklamani, Virginia G.
    Romero, Paula Munoz
    Vallespir, Bartomeu Piza
    Wasserman, Tomer
    Theall, Kathy Puyana
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Combined Inhibition of mTORC1 with Temsirolimus and HER2 with Neratinib: A Phase I/II Study in Patients with Metastatic HER2-Amplified or Triple-Negative Breast Cancer.
    Gajria, D.
    King, T.
    Pannu, H.
    Sakr, R.
    Seidman, A. D.
    Modi, S.
    Dickler, M.
    Drullinsky, P.
    Syldor, A.
    Sujata, P.
    Majid, M.
    Norton, L.
    Rosen, N.
    Chandarlapaty, S.
    CANCER RESEARCH, 2011, 71
  • [39] Preliminary results of a phase II study of lipoplatin (liposomal cisplatin)-vinorelbine combination as first line treatment in HER2/neu negative metastatic breast cancer (MBC)
    Farhat, F.
    Kattan, J.
    Ibrahim, K.
    Bitar, N.
    Haddad, N.
    Tamraz, S.
    Hatoum, H.
    Shamseddine, A.
    EJC SUPPLEMENTS, 2010, 8 (03): : 192 - 192
  • [40] Germline BRCA1 and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: Data from the German PRAEGNANT registry.
    Fasching, Peter A.
    Hu, Chunling
    Hart, Steven
    Hartkopf, Andreas D.
    Taran, Florin A.
    Janni, Wolfgang
    Tesch, Hans
    Haeberle, Lothar
    Ettl, Johannes
    Overkamp, Friedrich
    Lux, Michael P.
    Luftner, Diana
    Wallwiener, Markus
    Mueller, Volkmar
    Kolberg, Hans-Christian
    Fehm, Tanja N.
    Wallwiener, Diethelm
    Brucker, Sara
    Schneeweiss, Andreas
    Couch, Fergus
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345